| Sample | Title | Value | Rank |
|---|
| GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 29.6079 | 63 |
| GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 43.3087 | 68 |
| GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 24.7069 | 59 |
| GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 53.3842 | 71 |
| GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 65.7418 | 73 |
| GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 34.369 | 64 |
| GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 35.1221 | 64 |
| GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 46.6685 | 68 |
| GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 90.3111 | 76 |
| GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 38.869 | 66 |